Welcome to the e-CCO Library!

P704: Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. O'Connell1, P. McDonagh1, K. Hazel2, J. Fiona3, C. Dunne1,4, R. Farrell2, G. Harewood3, K. Hartery1,4, O. Kelly2, F. MacCarthy4,5, S. McKiernan1,4, F. Murray3, C. O'Morain6, O. Aoibhlinn3, D. Kevans1,4

Created: Friday, 22 February 2019, 9:41 AM
P704: Bifidobacterium longum species protect murine colitis through different activation repertoires of immune cells
Year: 2022
Source: ECCO'22
Authors: Kim, J.H.(1,2);I Seul, P.(1,2);Mijeong, S.(1,2);YooJin, S.(1,2);Kibeom, K.(1,2);Hyun Woo, M.(1,2);Tae Il, K.(1,2);Won Ho, K.(1,2);Seung Won, K.(1,2,3);Jae Hee, C.(1,2,3);
Created: Friday, 11 February 2022, 3:56 PM
P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mitrovic, M.(1)*;Marković, S.(1);Kalaba, A.(2);Zarić, D.(1);Kralj, Đ.(1);Milić, A.(2);Svorcan, P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P704: The impact of travel distance on disease outcomes in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borren N.*1,2, Tan W.1, Andrews E.1, Khalili H.1,3, Garber J.1,3, Yajnik V.1,3, Ananthakrishnan A.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, M. Noman1, I. Aerden1, M. Peeters3, E. Brouwers3, V. Ballet1, L. Vandersmissen1,3, G. Van Assche1,2, A. Gils3, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

Created: Thursday, 30 January 2020, 10:12 AM
P705: Incidence and risk factors of micronutrient deficiency in the patients with inflammatory bowel disease in Korea: folate, vitamin B12, 25-OH-vitamin D, ferritin
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. E. Park*1, S. J. Park2, Y. Park2, J. H. Cheon2, T. I. Kim2, W. H. Kim2

Created: Friday, 22 February 2019, 9:41 AM
P705: Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peerani F.*1, Chang H.2, Ungaro R.3, Torres J.3, Atreja A.3, Colombel J.-F.3

Created: Wednesday, 20 February 2019, 10:36 AM
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nowell, E.(1);Laird, S.(1);Bailey, E.(1);Brownson, E.(1)*;Saunders, J.(1);Seenan, J.P.(1);Smith, G.(1);Macdonald, J.(1);
Created: Friday, 14 July 2023, 11:12 AM
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD population
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.L. Hoivik1*, L.C. Buer1,2, N. Bolstad3, B. Moum1,2, A.W. Medhus1

Created: Thursday, 21 February 2019, 9:14 AM
P705: The effects of commonly consumed dietary fibres on the gut microbiome and its fibre fermentative capacity in adults with inflammatory bowel disease in remission
Year: 2022
Source: ECCO'22
Authors: Gerasimidis, K.(1);Nichols, B.(1);McGowan, M.(1);Svolos, V.(1);Papadopoulou, R.(1);Kokkorou, M.(1);Rebull, M.(1);Bello Gonzalez, T.(1);Hansen, R.(1);Russell, R.K.(1);Gaya, D.R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Swaine1, R. Reynolds2, X. Roblin3, D. Gibson1, C. Martin4, P. Irving2, M. Sparrow1, M. Ward1

Created: Thursday, 30 January 2020, 10:12 AM
P706: A distinct subset of tissue-resident Th17 cells expands in the inflamed intestines of Crohn’s Disease patients and responds to colitogenic bacteria
Year: 2022
Source: ECCO'22
Authors: ParoniPhD, M.(1);Leccese, G.(1);Ranzani, V.(2);Pagani, M.(3);Landini, P.(1);Vecchi, M.(4);Abrignani, S.(2);Facciotti, F.(5);Caprioli, F.(4);Geginat, J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P706: Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gordillo J.*1, Torres P.2, García-García de Paredes A.3, Llaό J.4, Lόpez San Román A.3, Domènech E.2, Garcia-Planella E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Kovacs1*, B. Kadleckova2, L. Gombosova3, L. Novotna4, E. Barlova4, J. Lucenincova5, P. Mikus6, M. Zakuciova3, Z. Zelinkova1

Created: Thursday, 21 February 2019, 9:14 AM
P706: Monitoring asymptomatic patients with Crohn's disease: the role of intestinal ultrasound
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dussias, N.(1)*;Melotti, L.(1);Mazzotta, E.(1);Decorato, A.(1);Vanigli, N.(1);Rizzello, F.(1);Gionchetti, P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P706: Patient knowledge towards biological treatment in inflammatory bowel diseases: a cross-sectional survey
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Wiśniewska-Jarosińska*1, M. Włodarczyk2, A. Gąsiorowska1, J. Fichna3, A. Sobolewska-Włodarczyk1

Created: Friday, 22 February 2019, 9:41 AM
P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Filip1,2, S. Jarmakiewicz - Czaja3, D. Piątek4, J. Sztembis5, A. Pękala1, W. Guz6

Created: Thursday, 30 January 2020, 10:12 AM
P707: 38 Weeks treatment of UC patients with different daily doses of mesalazine
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Laoun*1, R. Hofmann2

Created: Friday, 22 February 2019, 9:41 AM
P707: Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal study
Year: 2018
Source: ECCO '18 Vienna
Authors:

O. Björkqvist1*, D. Repsilber2, M. Seifert3, L. Engstrand3, I. Rangel2, J. Halfvarson2

Created: Thursday, 21 February 2019, 9:14 AM